Trump-Era Medicare Drug Price Negotiations Expose Government Overreach and Market Risks

In a move hailed by advocates as a victory for seniors, the Trump administration announced the inclusion of 15 new medications in the Medicare drug price negotiation program. This initiative allows the federal government to directly negotiate prices with pharmaceutical manufacturers for expensive and commonly used drugs covering conditions like Type 2 diabetes, HIV, arthritis, and several cancers. Is Government Negotiation the Solution or a Threat to Medical Innovation? At first glance, negotiating down prices for costly drugs sounds like a commonsense approach to relieve taxpayer burdens and ease out-of-control healthcare costs. Yet this so-called solution raises critical questions about...